ICML 2021 | Management of relapsed T-cell lymphoma
Steven Horwitz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses strategies to treat relapsed T-cell lymphoma. Patients with relapsed T-cell lymphoma who enter complete remission are more likely survive up to five years after treatment and certain subtypes including patients with angioimmunoblastic T-cell lymphoma will have especially good response rates. Dr Horwitz additionally mentions the need for novel therapies to serve as a bridge to allogeneic stem cell transplantation for complete remission. For transplant-ineligible patients, treatments such as valemetostat, romidepsin, or duvelisib can provide long-term efficacy for patient with few side effects. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
